Literature DB >> 7577019

Rectal cancer: the surgical options.

R J Heald1.   

Abstract

The hypothesis is considered that the tissue block relevant to optimal cure encompasses the integral visceral mesentery of the hind gut, or mesorectum. Surgical technique can recreate the tissue planes around an intact globular specimen which must not be torn or the margin compromised. This emphasis on the "perfect tumour package" has reduced the local recurrence rates in a consecutive personal series of 333 rectal cancer operations to 4% in those operated upon for cure. If patients with metastases or residual disease at presentation are included, the figure increases to 7%. Introduction of selective pre-operative high dose radiotherapy (DXT) for locally unfavourable cancers has combined with further attention to surgical detail to achieve a 5-year follow-up period (January 1990-January 1995) without a single case of locally recurrent disease. Problems remain with healing of the ultra-low anastomosis.

Entities:  

Mesh:

Year:  1995        PMID: 7577019     DOI: 10.1016/0959-8049(95)00160-k

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Anatomy of the lateral ligaments of the rectum: a controversial point of view.

Authors:  Guo-Jun Wang; Chun-Fang Gao; Dong Wei; Cun Wang; Wen-Jian Meng
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

2.  Single versus double stapling anastomotic technique in rectal cancer surgery.

Authors:  Z Radovanovic; T Petrovic; D Radovanovic; M Breberina; A Golubovic; D Lukic
Journal:  Surg Today       Date:  2013-06-26       Impact factor: 2.549

3.  Short-term preoperative radiotherapy in rectal cancer patients leads to a reduction of the detectable number of lymph nodes in resection specimens.

Authors:  K Maschuw; R Kress; A Ramaswamy; I Braun; P Langer; B Gerdes
Journal:  Langenbecks Arch Surg       Date:  2006-05-09       Impact factor: 3.445

4.  T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy.

Authors:  N B Merchant; J G Guillem; P B Paty; W E Enker; B D Minsky; S H Quan; D Wong; A M Cohen
Journal:  J Gastrointest Surg       Date:  1999 Nov-Dec       Impact factor: 3.452

5.  The modern abdominoperineal excision: the next challenge after total mesorectal excision.

Authors:  Roger Marr; Kevin Birbeck; James Garvican; Christopher P Macklin; Nicholas J Tiffin; Wendy J Parsons; Michael F Dixon; Nicholas P Mapstone; David Sebag-Montefiore; Nigel Scott; David Johnston; Peter Sagar; Paul Finan; Philip Quirke
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

6.  Short-term preoperative radiotherapy is a safe approach for treatment of locally advanced rectal cancer.

Authors:  D P Korkolis; G D Plataniotis; E Gondikakis; D Xinopoulos; G V Koulaxouzidis; J Katsilieris; P P Vassilopoulos
Journal:  Int J Colorectal Dis       Date:  2005-06-10       Impact factor: 2.571

7.  Role of intraoperative frozen section for assessing distal resection margin after anterior resection.

Authors:  Rachel M Gomes; Manish Bhandare; Ashwin Desouza; Munita Bal; Avanish P Saklani
Journal:  Int J Colorectal Dis       Date:  2015-05-16       Impact factor: 2.571

8.  Influencing factors of symptomatic anastomotic leakage after anterior resection of the rectum for cancer.

Authors:  Zhi-jie Cong; Chuan-gang Fu; Han-tao Wang; Lian-jie Liu; Wei Zhang; Hao Wang
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

9.  Prediction of anastomotic leakage after anterior rectal resection.

Authors:  Shubang Cheng; Bolin He; Xueyi Zeng
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

10.  Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report.

Authors:  Silvia Cresti; Mehdi Ouaïssi; Igor Sielezneff; Jean-Baptiste Chaix; Nicolas Pirro; Bruno Berthet; Bernard Consentino; Bernard Sastre
Journal:  World J Surg Oncol       Date:  2008-12-23       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.